Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is associate uncommon, however probably fatal, reason behind disease that's related to prescription medications, OTC drugs, and seasoner and dietary supplements (HDS). DILI has 2 types: intrinsic and individual. Patient, environmental, and drug-related factors might play a task within the pathologic process of DILI. within the us, antibiotics and anticonvulsant medicine square measure the foremost common drug categories related to DILI, however HDS square measure on the increase as a cause. Management of DILI involves the removal of the offensive agent and also the use of N-acetylcysteine for acetaminophen-induced liver injury. Outcomes vary counting on the drug used and sort of liver injury sustained. Pharmacists will play a necessary role within the analysis of DILI, particularly in patients taking multiple medications and supplements. Drug-induced liver injury (DILI; conjointly referred to as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), seasoner and dietary supplements (HDS), or alternative
xenobiotics that end in abnormalities in liver tests or in viscus
pathology that can't be explained by alternative causes.1 There square measure 2 kinds of DILI: intrinsic and individual. Intrinsic DILI refers to liver toxicity evoked by a drug in a very sure and dose-related manner (e.g., Anacin III [APAP]); individual DILI, that happens less oft, is related to a less consistent dose-toxicity relationship and a a lot of varied presentation.
High Impact List of Articles
-
Pathological phenotype in familial neurodegenerative disease: implications for families and therapeutic constructs
Rudy J Castellani, Hyoung-gon Lee, Robert B Petersen, Xiongwei Zhu and George Perry
Review Article: Clinical Practice
-
Pathological phenotype in familial neurodegenerative disease: implications for families and therapeutic constructs
Rudy J Castellani, Hyoung-gon Lee, Robert B Petersen, Xiongwei Zhu and George Perry
Review Article: Clinical Practice
-
Fertility preservation in ovarian cancer
Rebecca Arend, Anne Holland, Caryn St Clair and Thomas J Herzog
Review Article: Clinical Practice
-
Fertility preservation in ovarian cancer
Rebecca Arend, Anne Holland, Caryn St Clair and Thomas J Herzog
Review Article: Clinical Practice
-
Mepolizumab in the treatment of eosinophilic esophagitis
Rana F Ammoury and Sandeep K Gupta
Drug Evaluation: Clinical Practice
-
Mepolizumab in the treatment of eosinophilic esophagitis
Rana F Ammoury and Sandeep K Gupta
Drug Evaluation: Clinical Practice
-
New drug for Hepatitis C in Phase II trials
Bulletin Board: Clinical Practice
-
New drug for Hepatitis C in Phase II trials
Bulletin Board: Clinical Practice
-
Decitabine in myelodysplastic syndromes
Elias Jabbour, Hagop M Kantarjian, Guillermo Garcia-Manero and Jean-Pierre J Issa
Drug Evaluation: Clinical Practice
-
Decitabine in myelodysplastic syndromes
Elias Jabbour, Hagop M Kantarjian, Guillermo Garcia-Manero and Jean-Pierre J Issa
Drug Evaluation: Clinical Practice
Relevant Topics in Clinical